Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
272 studies found for:    "systemic scleroderma"
Show Display Options
Rank Status Study
21 Recruiting Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Conditions: Scleroderma, Diffuse;   Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: IVA337;   Drug: Placebo
22 Withdrawn Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
Condition: Systemic Scleroderma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: rituximab;   Drug: cyclophosphamide;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
23 Recruiting Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
Conditions: Systemic Sclerosis;   Scleroderma;   Interstitial Lung Disease;   Lung Fibrosis
Interventions: Drug: Cyclophosphamide;   Drug: Placebo
24 Recruiting IL1-TRAP, Rilonacept, in Systemic Sclerosis
Conditions: Scleroderma;   Systemic Sclerosis;   Diffuse Scleroderma;   Diffuse Systemic Sclerosis
Interventions: Drug: Rilonacept;   Drug: Placebo
25 Unknown  Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis
Conditions: Systemic Scleroderma;   Systemic Sclerosis
Interventions: Radiation: UVA1;   Other: UVA1
26 Unknown  Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Conditions: Scleroderma, Systemic;   Scleroderma, Diffuse;   Scleroderma, Limited;   Raynaud Phenomenon
Interventions: Drug: Sildenafil citrate;   Drug: Placebo
27 Recruiting Scleroderma Registry
Conditions: Systemic Sclerosis;   Scleroderma
28 Recruiting Duke Scleroderma Clinic Patient Registry
Conditions: Scleroderma;   Systemic Sclerosis
Intervention: Other: Registry
29 Recruiting Scleroderma Registry & Repository at the Hospital for Special Surgery
Condition: Scleroderma
30 Active, not recruiting Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Conditions: Scleroderma;   Systemic Sclerosis;   Raynaud Phenomena;   Raynaud's Disease
Interventions: Device: Celution Device;   Other: Placebo
31 Recruiting Scleroderma Treatment With Autologous Transplant (STAT) Study
Condition: Systemic Scleroderma
Interventions: Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
32 Terminated Immunoadsorption in Patients With Severe Systemic Sclerosis
Condition: Systemic Scleroderma
Intervention: Device: TheraSorb Ig
33 Recruiting Zibotentan Better Renal Scleroderma Outcome Study
Conditions: Scleroderma;   Scleroderma Renal Crisis;   Chronic Kidney Disease
Intervention: Drug: Zibotentan
34 Completed
Has Results
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Conditions: Scleroderma, Diffuse;   Scleroderma, Systemic
Intervention: Drug: Abatacept
35 Completed Oral Type I Collagen for Relieving Scleroderma
Conditions: Scleroderma;   Connective Tissue Diseases
Interventions: Drug: Oral bovine type I collagen;   Drug: Placebo
36 Completed
Has Results
High Dose Cyclophosphamide for Treatment of Scleroderma
Condition: Scleroderma
Intervention: Drug: IV Cyclophosphamide
37 Recruiting Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension
Conditions: Systemic Sclerosis;   Pulmonary Hypertension;   Scleroderma
Intervention: Other: No intervention given
38 Completed Effectiveness and Safety of Lidocaine for Scleroderma
Condition: Scleroderma
Interventions: Drug: Lidocaine 2% without vessel constrictor;   Other: Placebo - physiological solution 0,9%
39 Recruiting Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
Conditions: Scleroderma;   Interstitial Lung Disease
Intervention: Drug: dabigatran etexilate
40 Active, not recruiting Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years